enfr

SCN’s vision is to capitalize upon Canada’s competitive advantage in stem cells for the benefit of Canadians.

The Stem Cell Network (SCN) is a national non-profit that supports stem cell and regenerative medicine research, training the next generation and outreach across Canada. SCN’s goal is to translate science from the lab to clinical applications, commercial products and public policy for the benefit of Canadians. SCN is supported by the Government of Canada and works in partnership with industry representatives, health charities, government and non-government organizations to build on Canada’s leadership in the sector. Since 2001, SCN has directed an investment of over $100M of strategic funding that has benefitted approximately 170 world-class research groups and 3,000 trainees, and has catalyzed 19 clinical trials.

SCN was founded on a core set of organizational values that have shaped the way it has conducted itself over the past 18 years. The SCN community shares these common values and works to ensure they are expressed in all that it does:

• Requiring research excellence, integrity and a commitment to ethical practice;
• Fostering collaboration;
• Fostering equity, diversity and inclusion;
• Driving innovation; and
• Supporting continual learning and improvement.

3,000

Trainees

170

Research Groups

$118M

In Research, Training and Outreach

$116M

In Partner Support

Join our Team! Trainee Communications Committee (TCC)

The Stem Cell Network (SCN) is currently seeking enthusiastic and dynamic trainees to participate on SCN’s Trainee Communications Committee (TCC) from April 1, 2020 to March 31, 2021. This committee will play an important part in the development of SCN’s training program for young investigators.

Read more

In the news

New stem cell technology gives high-risk leukemia patients second chance at life

Positive results from a recent clinical trial show that a Canadian-made stem cell innovation could reduce risks and improve outcomes of cord blood stem cell transplantation for patients with leukemia and lymphoma. OTTAWA, November 5, 2019 — Few people get a second chance at life. And fewer still are forced to take it before their …

Read more